Schrodinger, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+8.60%
vs ±12.1% implied · ×0.71
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
shaded = implied · ▲▼ = realized
Schrodinger, Inc.
27.14
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $171.0M | 16.01% | +8.71% |
| Bill & Melinda Gates Foundation Trust | $113.5M | 10.62% | 0.00% |
| Rubric | $104.0M | 9.74% | +6.67% |
| Vanguard Portfolioindex-like | $61.5M | 5.76% | −1.94% |
| Sumitomo Mitsui Trust | $44.0M | 4.12% | −15.19% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $171.0M | 16.01% | +8.71% |
| Bill & Melinda Gates Foundation Trust | $113.5M | 10.62% | 0.00% |
| Rubric | $104.0M | 9.74% | +6.67% |
| Vanguard Portfolioindex-like | $61.5M | 5.76% | −1.94% |
| Sumitomo Mitsui Trust | $44.0M | 4.12% | −15.19% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Schrodinger, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Schrodinger, Inc.'s 6 closest co-movers, none share that code.
Linked news
Bull1
Bear0
—
Expected move
Inputs8Q avg ±5.1%·×2.62·rich
straddle ±18.1%
spot 27.14exp Nov 20ATM strike 27.5ATM straddle 5.77IV 110%